全球射血分数降低心衰指南推荐药物处方的差异
REPORT-HF前瞻性研究纳入44国8669例HFrEF住院患者,评估出院及6个月随访时RAS抑制剂、β受体阻滞剂和醛固酮受体拮抗剂的处方率与剂量。仅37%出院时和34%存活者6个月时使用全部三类药物,中低收入国家比例更低(出院19% vs 高收入国家41%)。使用≥50%指南推荐剂量的RAS抑制剂和β受体阻滞剂与1年生存改善独立相关。
要点
- HFrEF患者指南推荐药物使用率低,全球仅37%出院时使用全部三类。
- 中低收入国家患者使用率显著低于高收入国家(出院19% vs 41%)。
- 使用≥50%推荐剂量的RAS抑制剂和β受体阻滞剂与1年生存改善独立相关。
核心结论
- 中低收入国家HFrEF患者接受指南推荐药物及目标剂量的可能性更低,改善药物可及性可能减少国际结局差异。
研究设计与样本
- REPORT-HF前瞻性研究,纳入44国8669例HFrEF住院患者(低等收入国家1458例、中等收入国家3363例、高收入国家3848例),评估出院和6个月随访处方率与剂量。
主要发现
- 出院时仅37%、6个月时仅34%存活者使用全部三类药物(RAS抑制剂、β受体阻滞剂、醛固酮受体拮抗剂)。
- 中低收入国家使用全部三类药物的比例低于高收入国家:出院时19% vs 41%,6个月时15% vs 37%。
- 女性、无医疗保险、中低收入国家来源及出院后6个月内无计划医疗随访的患者,独立于混杂因素,最不可能达到目标剂量。
- 使用≥50%指南推荐剂量的RAS抑制剂和β受体阻滞剂与更好的1年生存独立相关,不论国家收入水平。
临床怎么用
- 应关注HFrEF患者出院时及随访中指南推荐药物(RAS抑制剂、β受体阻滞剂、醛固酮受体拮抗剂)的启用与剂量上调。
- 对女性、无保险、中低收入国家及无早期随访计划的高危患者,需加强干预以提高目标剂量治疗率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure (HF) is a global challenge, with lower- and middle-income countries (LMICs) carrying a large share of the burden. Treatment for HF with reduced ejection fraction (HFrEF) improves survival but is often underused. Economic factors might have an important effect on the use of medicines. METHODS AND RESULTS: This analysis assessed prescription rates and doses of renin-angiotensin system (RAS) inhibitors, β-blockers, and mineralocorticoid receptor antagonists at discharge and 6-month follow-up in 8669 patients with HFrEF (1458 from low-, 3363 from middle-, and 3848 from high-income countries) hospitalized for acute HF in 44 countries in the prospective REPORT-HF study. We investigated determinants of guideline-recommended treatments and their association with 1-year mortality, correcting for treatment indication bias.Only 37% of patients at discharge and 34% of survivors at 6 months were on all three medication classes, with lower proportions in LMICs than high-income countries (19 vs. 41% at discharge and 15 vs. 37% at 6 months). Women and patients without health insurance, or from LMICs, or without a scheduled medical follow-up within 6 months of discharge were least likely to be on guideline-recommended medical therapy at target doses, independent of confounders. Being on ≥50% of guideline-recommended doses of RAS inhibitors, and β-blockers were independently associated with better 1-year survival, regardless of country income level. CONCLUSION: Patients with HFrEF in LMICs are less likely to receive guideline-recommended drugs at target doses. Improved access to medications and medical care could reduce international disparities in outcome.
引用
- Tromp, Ouwerkerk, Teng, et al. Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. Eur Heart J. 2022. PMID: 35393622. doi:10.1093/eurheartj/ehac103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。